Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CDMO Avid Bioservices, Inc.

停牌 03-02 18:57:07 EST

12.49

+0.00

0.00%

最高12.49	最低12.49	成交量0.00
今开12.49	昨收12.49	日振幅0.00%
总市值7.99亿	流通市值6.32亿	总股本6,396万
成交额3,832万	换手率0.00%	流通股本5,062万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.49,"timestamp":1738702800000,"preClose":12.49,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":50623090,"shares":63963302,"eps":-2.394638,"marketStatus":"停牌","change":0,"latestTime":"03-02 18:57:07 EST","open":12.49,"high":12.49,"low":12.49,"amount":38318611.149448,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.394638,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772499600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.49,"volumeRatio":0},"requestUrl":"/m/hq/s/CDMO","defaultTab":"news","newsList":[{"id":"2613748599","title":"美国OTC市场Scorpius Holdings, Inc.盘中异动 下午盘快速上涨72.41%报0.010美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613748599?lang=zh_cn&edition=full","pubTime":"2026-02-24 03:17","pubTimestamp":1771874221,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日03时17分，美国OTC市场Scorpius Holdings, Inc.股票出现波动，股价快速上涨72.41%。截至发稿，该股报0.010美元/股，成交量833股，换手率0.00%，振幅72.41%。美国OTC市场Scorpius Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.43%。美国OTC市场Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224031701a716badc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224031701a716badc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SCPX","CDMO","BK4139"],"gpt_icon":0},{"id":"2610568695","title":"高盛：今年内地医疗板块更依赖数据及盈利能见度 看好CDMO企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2610568695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610568695?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:08","pubTimestamp":1770617323,"startTime":"0","endTime":"0","summary":"今年要获得超越行业的回报，更依赖于关键数据公布、实际成交，以及盈利兑现或转折点的能见度。该行对医疗器械板块维持中性看法，虽然行业已触底，但需时逐步复苏；推荐买时代天使及威高股份。医疗服务板块方面，该行仍持相对谨慎态度，因成本控制措施的持续影响，以及疲弱的消费周期；下调海吉亚医疗评级至“中性”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","02359","BK1589","LU2242644610.SGD","BK1141","BK1191","LU0196878994.USD","CDMO","06990","02696","LU2045819591.USD","LU0052750758.USD","LU0708995583.HKD","BK1583","HK0000320223.HKD","SG9999014674.SGD","BK1161","HK0000306701.USD","LU2125910500.SGD","BK4139","02268","LU0320764599.SGD","LU1046422090.SGD","BK1576","LU2488822045.USD","HK0000306685.HKD","HK0000165453.HKD","HK0000320264.USD","159891"],"gpt_icon":0},{"id":"2607049601","title":"外资CDMO纷纷易手，它们在华消失殆尽了 | 海斌访谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049601","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607049601?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:58","pubTimestamp":1769781533,"startTime":"0","endTime":"0","summary":"“不光是在收缩，是在消失。”澳斯康创始人罗顺近期接受第一财经记者采访时，这样评价跨国CDMO在华业务。CDMO是指合同研发和生产组织，它是制药产业链分工日益专业化的结果。2020年左右，一大批知名跨国企业如龙沙、赛默飞世尔、默克等都在中国投资了CDMO业务，并对中国业务寄予厚望。现在，潮水已经退去。目前，还在中国开展CDMO业务的跨国企业几乎只有德国的勃林格殷格翰了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637350971.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637350971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2603991833","title":"515亿温州富豪，28亿吞并苏州药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2603991833","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603991833?lang=zh_cn&edition=full","pubTime":"2026-01-16 21:42","pubTimestamp":1768570978,"startTime":"0","endTime":"0","summary":"温州医药首富李革，拿下一家同行。1月14日晚，他实控的药明合联，宣布将以现金要约方式，以31亿港元的估值，约合28亿人民币，控股东曜药业。李革的药明系较为慷慨，出价4港元/股，相较12月下旬2港元左右的股价，刚好溢价一倍，考虑部分购股权注销价为1.7665港元，其要约最高代价约27.9亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622167671.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622167671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0039217434.USD","LU0327786744.USD","LU0516422366.SGD","BK1521","LU0823426308.USD","LU0140636845.USD","LU0326950275.SGD","LU0516422952.EUR","LU0456827905.SGD","LU0359201612.USD","LU0359202008.SGD","LU3063872942.SGD","LU0588546209.SGD","02268","SG9999002562.SGD","LU2039709279.SGD","02269","LU0708995583.HKD","LU1720050803.USD","LU0307460666.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU1794554557.SGD","LU2488822045.USD","BK1576","LU0456846285.SGD","LU0348825331.USD","LU0572944931.SGD","LU0348735423.USD","LU0181495838.USD","LU0417516738.SGD","LU0516423174.USD","LU0516423091.SGD","BK1610","LU1242518931.SGD","BK1589","LU0051755006.USD","LU1242518857.USD","CDMO","LU0979878070.USD","SG9999002463.SGD","SG9999014674.SGD","LU0516422440.USD","LU0856984785.SGD","BK4139","LU0043850808.USD","LU0823426480.USD","LU0052750758.USD","BK1141","LU1688375341.USD"],"gpt_icon":0},{"id":"2603610556","title":"业绩盈喜, 控股收购东曜药业，药明合联(02268)进一步稳固ADC CDMO市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2603610556","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603610556?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:32","pubTimestamp":1768404738,"startTime":"0","endTime":"0","summary":"同时，通过此次控股收购，药明合联亦希望进一步丰富其项目组合并扩大其客户群，稳固其在 ADC CDMO 领域的领导地位。药明合联早已布局人才梯队建设，截至2025年底，团队规模已突破2600人。截至2025年12月底，药明合联在全球合作客户数量已超过630家，iCMC项目总数达到252个。这一举措不仅能实现产能的本地化交付，更能进一步深化公司在全球生物偶联药CDMO领域的市场覆盖，巩固行业领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","SG9999014674.SGD","ADC","LU2488822045.USD","BK4139","02268","CDMO","BK1141","BK4080"],"gpt_icon":1},{"id":"2603664448","title":"里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664448?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:20","pubTimestamp":1768371626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，展望2026年，相信对中国医疗板块而言，盈利交付将比估值扩张更为重要，料药明康德 有望跑赢同业。该行将药明康德列为中国CRO/CDMO行业的首选。该行维持药明康德“跑赢大市”评级及目标价143.4港元。相较同行，药明康德具备更强的盈利增长可见性：其2025年前三季度订单储备同比增长41%，远高于全球平均约14%，即使在地缘政治风险持续的背景下仍保持强劲增势。该行预计2026年药明康德的订单增速将继续领先全球同行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603259","BK0028","02359","BK4139","LU2488822045.USD","BK0216","BK0082","LU1997245177.USD","LU2495084118.USD","LU2045819591.USD","BK0010","LU0456842615.SGD","CDMO","LU2242644610.SGD","LU1969619763.USD","LU0320764599.SGD","BK0185","LU1808992512.USD","600056","BK1141","LU1934453819.USD","BK0250","LU1997245094.SGD","LU1997244956.HKD","BK1583","LU1046422090.SGD","LU1979443071.USD","LU2328871848.SGD","BK0175","BK1576","LU0708995583.HKD","LU2125910500.SGD","LU0052750758.USD","BK0188"],"gpt_icon":0},{"id":"2603769682","title":"雅本化学：公司与恒瑞医药的合作模式为CDMO模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769682","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769682?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:38","pubTimestamp":1768311484,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，雅本化学在互动平台回答投资者提问时表示，公司与恒瑞医药的合作模式为CDMO模式，覆盖恒瑞医药从临床前到商业化生产的各个阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617688110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","BK1191","BK0196","LU0405327148.USD","LU2580892862.HKD","LU0359201885.HKD","CDMO","BK0028","600276","LU0359202008.SGD","BK0012","LU1328615791.USD","LU1997245094.SGD","LU1969619763.USD","LU1580142542.USD","LU2495084118.USD","BK0174","LU2289578879.USD","BK4139","LU1023057109.AUD","LU2580892789.USD","BK0183","BK0239","LU1146622755.USD","BK0188","300261","LU1820825898.SGD","LU1064131003.USD","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","BK0060","LU2543165471.USD","LU1781817850.SGD","LU2097828631.EUR","LU0359201612.USD","LU2488822045.USD","LU2097828714.EUR","LU1997244956.HKD","BK0229","LU1255011170.USD","LU2148510915.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2586020682","title":"乐普生物-B(02157)与乐普医疗订立CDMO服务框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2586020682","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586020682?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:48","pubTimestamp":1764319714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，于2025年11月28日，本公司与乐普医疗订立CDMO服务框架协议，本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外，本集团可在适当的商机出现时更有效利用富余产能。董事认为，订立CDMO服务框架协议将能更有效利用本集团的富余产能，可为本集团整体产生补充现金流量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDMO","BK0113","BK0042","BK0251","BK0201","300003","BK0196","BK0114","BK4139","BK1161","02157","BK0028","BK0188"],"gpt_icon":0},{"id":"2585435821","title":"中信建投：CXO行业调整基本完成 重点关注出海能力强的CDMO企业及临床CRO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435821?lang=zh_cn&edition=full","pubTime":"2025-11-24 07:36","pubTimestamp":1763940962,"startTime":"0","endTime":"0","summary":"CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。从国际比较优势看，中国具备人口与内需优势、制造与供应链优势，同时创新能力快速提升，中国资产出海数量也持续提升。2025年下半年我们重点关注的是药品和耗材集采政策优化、多元化支付及医疗服务价格改革。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","601066","BK0276","CDMO","BK4139"],"gpt_icon":0},{"id":"2581004467","title":"美国OTC市场Scorpius Holdings, Inc.盘中异动 快速拉升83.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581004467?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:46","pubTimestamp":1762353970,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日22时46分，美国OTC市场Scorpius Holdings, Inc.股票出现波动，股价急速上涨83.33%。美国OTC市场Scorpius Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。美国OTC市场Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105224610a48ae644&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105224610a48ae644&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SCPX","CDMO"],"gpt_icon":0},{"id":"2575528710","title":"桂林三金：白帆生物的CDMO订单中有一部分为海外订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2575528710","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575528710?lang=zh_cn&edition=full","pubTime":"2025-10-16 18:08","pubTimestamp":1760609280,"startTime":"0","endTime":"0","summary":"证券日报网讯桂林三金10月16日在互动平台回答投资者提问时表示，白帆生物的CDMO订单中有一部分为海外订单。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-16/doc-infuauti2451088.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-16/doc-infuauti2451088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002275","BK0060","CDMO","BK0188","BK0239","BK4139","BK0028"],"gpt_icon":0},{"id":"2575404910","title":"Lifecore Biomedical, Inc.盘中异动 早盘股价大涨7.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575404910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575404910?lang=zh_cn&edition=full","pubTime":"2025-10-13 21:30","pubTimestamp":1760362229,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日21时30分，Lifecore Biomedical, Inc.股票出现异动，股价大幅上涨7.84%。Lifecore Biomedical, Inc.股票所在的制药行业中，整体涨幅为0.00%。Lifecore Biomedical, Inc.公司简介：Lifecore Biomedical Inc 是一家完全集成的合同开发和制造组织 ，提供注射器、西林瓶和药筒等复杂无菌注射剂产品的开发、灌装和成品服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013213029a6b7306b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013213029a6b7306b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDMO","BK4121","BK4139","LFCR","BK4212"],"gpt_icon":0},{"id":"2575473526","title":"大摩：美国最新生物安全法案对中资CDMO更为有利","url":"https://stock-news.laohu8.com/highlight/detail?id=2575473526","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575473526?lang=zh_cn&edition=full","pubTime":"2025-10-13 15:32","pubTimestamp":1760340742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，美国参议院日前通过将《生物安全法案》纳入《国防授权法案》的动议;修订版本较为温和，允许被点名企业可申辩与上诉，亦未有在生物科技章节点名药明系企业。法案仍需经参众两院共同通过，并由总统签署方能正式立法。该行预期中资药物合同研发生产机构(CDMO)股份初期将经历波动，因表面来看该法案让美国政府有新工具，可限制本地企业与中国供应商合作。不过，相较去年12月旧版法案遭众议院民主党阻拦前，当前的结果更为有利。中资CDMO股票年内累升84%，已部分反映投资者对地缘政治和脱钩风险缓和的预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2570105079","title":"信达证券：CXO市场景气度正在修复 CDMO布局新兴赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2570105079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570105079?lang=zh_cn&edition=full","pubTime":"2025-09-26 13:57","pubTimestamp":1758866254,"startTime":"0","endTime":"0","summary":"受益于多肽、ADC等新分子需求旺盛，CDMO龙头普遍已经开始布局这些新兴赛道，带动相关业务实现不断高增长。信达证券主要观点如下：CXO整体供需关系改善，市场景气度正在修复需求侧：CXO行业本质上属于“卖水人”商业模式，其景气度和生物医药行业投融资高度相关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK0276","LU2488822045.USD","SG9999002463.SGD","06127","LU0181495838.USD","LU0348825331.USD","LU1688375341.USD","LU0456846285.SGD","LU0572944931.SGD","LU0359201612.USD","LU0856984785.SGD","LU0359202008.SGD","LU0823426480.USD","LU0348735423.USD","601059","06821","LU0140636845.USD","LU0039217434.USD","LU0708995583.HKD","LU1794554557.SGD","LU0417516738.SGD","SG9999014674.SGD","02269","CDMO","02359","02268","BK1576","CXO","LU2125910500.SGD","LU2045819591.USD","LU0516423174.USD","LU0052750758.USD","LU0819121731.USD","BK1589","LU0307460666.USD","LU1720050803.USD","LU0516423091.SGD","LU2242644610.SGD","LU1046422090.SGD","LU0516422440.USD","LU0516422952.EUR","LU1880383366.USD","SG9999002562.SGD","IE00B0JY6N72.USD","BK1191","BK1141","03759","BK4139","LU0823426308.USD"],"gpt_icon":0},{"id":"2570180047","title":"Lifecore Biomedical, Inc.盘中异动 股价大跌5.03%报6.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570180047","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570180047?lang=zh_cn&edition=full","pubTime":"2025-09-25 21:58","pubTimestamp":1758808708,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日21时58分，Lifecore Biomedical, Inc.股票出现异动，股价大幅下跌5.03%。Lifecore Biomedical, Inc.股票所在的制药行业中，整体跌幅为0.56%。Lifecore Biomedical, Inc.公司简介：Lifecore Biomedical Inc 是一家完全集成的合同开发和制造组织 ，提供注射器、西林瓶和药筒等复杂无菌注射剂产品的开发、灌装和成品服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925215828a69ddbcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925215828a69ddbcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4212","BK4121","LFCR","CDMO"],"gpt_icon":0},{"id":"2569717644","title":"CDMO巨头“问题工厂”再爆雷！明星SMA药物遭拒批","url":"https://stock-news.laohu8.com/highlight/detail?id=2569717644","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569717644?lang=zh_cn&edition=full","pubTime":"2025-09-23 23:03","pubTimestamp":1758639780,"startTime":"0","endTime":"0","summary":"根据FDA的拒批函，问题出在Catalent印第安纳有限责任公司的生产场地。这些观察结果并非apitegromab专属问题，且FDA未提及任何其他影响审批的顾虑，包括药物的疗效或安全性缺陷。从市场反应来看，此次拒批并非完全出乎意料。此次apitegromab因生产端问题折戟审批，不仅让Scholar Rock的研发进程遇阻，也为SMA患者的治疗选择增添了变数。后续该“问题工厂”的整改进展及apitegromab的重新申报动态，将持续受到行业关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092400192995407d4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092400192995407d4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4139","CDMO","LU1093756168.USD","BK4007","BK4585","BK4217","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","SMA","BK4599"],"gpt_icon":1},{"id":"2566623616","title":"国盛证券：首予维亚生物(01873)“买入”评级 CDMO与孵化生态协同打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2566623616","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566623616?lang=zh_cn&edition=full","pubTime":"2025-09-10 10:09","pubTimestamp":1757470181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国盛证券发布研报称，首次覆盖，给予维亚生物“买入”评级，预计2025-2027年归母净利润分别为2.21亿元、2.64亿元、3.44亿元，增速为32%、20%、30%，PE为24X、20X、15X。该行表示，作为一站式CRO+CDMO平台，公司受益于全球医药研发外包需求的持续增长。2024年下半年CRO收入已实现同比、环比双增长，显示业务拐点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01873","CDMO","161027"],"gpt_icon":0},{"id":"2566766171","title":"维亚生物盘中异动 下午盘股价大跌5.00%报2.660港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566766171","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566766171?lang=zh_cn&edition=full","pubTime":"2025-09-09 14:01","pubTimestamp":1757397669,"startTime":"0","endTime":"0","summary":"2025年09月09日下午盘14时01分，维亚生物股票出现异动，股价快速下跌5.00%。截至发稿，该股报2.660港元/股，成交量686.4万股，换手率0.32%，振幅6.07%。资金方面，该股资金流入625.593万港元，流出1149.93万港元。维亚生物股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，思路迪医药股份、三叶草生物-B、方达控股涨幅较大，振幅较大的相关个股有三叶草生物-B、圣诺医药-B、思路迪医药股份，振幅分别为19.69%、19.26%、17.61%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909140109a71893da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909140109a71893da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2518609222","title":"Scorpius Holdings, Inc.盘中异动 早盘股价大跌6.63%报0.155美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518609222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518609222?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:34","pubTimestamp":1741613697,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时34分，Scorpius Holdings, Inc.股票出现异动，股价急速下挫6.63%。截至发稿，该股报0.155美元/股，成交量8.9466万股，换手率1.54%，振幅0.06%。Scorpius Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213457964036c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213457964036c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDMO","BK4139","SCPX"],"gpt_icon":0},{"id":"2517165140","title":"Scorpius Holdings, Inc.盘中异动 股价大涨5.95%报0.155美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517165140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517165140?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:36","pubTimestamp":1741271783,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时36分，Scorpius Holdings, Inc.股票出现异动，股价快速上涨5.95%。Scorpius Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1031.57%、168.57%、53.05%，振幅较大的相关个股有Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为24.20%、23.83%、23.12%。Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223623989eb55c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223623989eb55c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SCPX","CDMO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avid Bioservices, Inc.最初于1981年6月在美国加州注册成立，并于1996年9月25日在美国特拉华州重新合并。该公司是一家专门的合同开发和制造组织（“CDMO”），提供从工艺开发到当前良好制造实践的全方位服务（“CGMP”）临床和商业制造，专注于从哺乳动物细胞培养中提取生物制药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.245054},{"month":2,"riseRate":0.580645,"avgChangeRate":0.056406},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073378},{"month":12,"riseRate":0.419355,"avgChangeRate":0.023819}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}